Exciva GmbH
Privately held: no public share price · Germany
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule | Alzheimer's Disease | |
| Phase 2/3 | NMDA receptor / 5-HT2A receptorSmall molecule | Alzheimer's Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
January 2029 (1)
Est. primary completion 2029-01 · NCT07284472 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.